GUIDE-HF试验:肺动脉压监测在心力衰竭中的应用——COVID-19大流行的影响
GUIDE-HF研究比较血流动力学指导管理与常规管理对心衰患者全因死亡和心衰事件的影响。COVID-19前治疗组主要终点事件率显著低于对照组(HR 0.81,P=0.049),但疫情期间差异消失(HR 1.11,P=0.526),对照组事件率下降21%,治疗组无变化。研究提示患者相关因素可能在其中起重要作用。
要点
- COVID-19前血流动力学指导管理可降低心衰事件风险。
- 疫情期间治疗组与对照组主要终点事件率差异消失。
- 肺动脉压下降但药物调整减少,提示患者相关因素作用。
核心结论
- COVID-19期间对照组主要终点事件率下降,治疗组保持低水平,导致原本存在的组间差异消失。
- 这些结果并非由提供者或疾病相关因素变化引起,肺动脉压下降而药物调整减少,提示患者相关因素起重要作用。
研究设计与样本
- GUIDE-HF研究为随机对照试验,2018年3月15日至2019年12月20日入组患者,随机分配至血流动力学指导管理组(治疗组)或对照组,随访12个月。
- 主要终点为全因死亡加心衰事件。
主要发现
- COVID-19前,主要终点事件率治疗组 vs 对照组为0.553 vs 0.682事件/患者年(HR 0.81,P=0.049)。
- COVID-19期间,治疗差异不再明显(HR 1.11,P=0.526),对照组事件率下降21%至0.536事件/患者年,治疗组无变化(0.597事件/患者年)。
- COVID-19期间,治疗组每月药物调整率下降19.2%,对照组下降10.7%,两组间无差异(P=0.362)。
- 肺动脉压曲线下面积治疗组减少-98 mmHg-days,对照组减少-100 mmHg-days(P=0.867)。
- 两组受试者接触频率在COVID-19前后相似,患者对研究方案的依从性在疫情期间维持。
临床怎么用
- 疫情期间心衰事件率的变化需考虑患者相关因素对血流动力学指导管理效果的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: During the coronavirus disease 2019 (COVID-19) pandemic, important changes in heart failure (HF) event rates have been widely reported, but few data address potential causes for these changes; several possibilities were examined in the GUIDE-HF study. METHODS AND RESULTS: From 15 March 2018 to 20 December 2019, patients were randomized to haemodynamic-guided management (treatment) vs. control for 12 months, with a primary endpoint of all-cause mortality plus HF events. Pre-COVID-19, the primary endpoint rate was 0.553 vs. 0.682 events/patient-year in the treatment vs. control group [hazard ratio (HR) 0.81, P = 0.049]. Treatment difference was no longer evident during COVID-19 (HR 1.11, P = 0.526), with a 21% decrease in the control group (0.536 events/patient-year) and no change in the treatment group (0.597 events/patient-year). Data reflecting provider-, disease-, and patient-dependent factors that might change the primary endpoint rate during COVID-19 were examined. Subject contact frequency was similar in the treatment vs. control group before and during COVID-19. During COVID-19, the monthly rate of medication changes fell 19.2% in the treatment vs. 10.7% in the control group to levels not different between groups (P = 0.362). COVID-19 was infrequent and not different between groups. Pulmonary artery pressure area under the curve decreased -98 mmHg-days in the treatment group vs. -100 mmHg-days in the controls (P = 0.867). Patient compliance with the study protocol was maintained during COVID-19 in both groups. CONCLUSION: During COVID-19, the primary event rate decreased in the controls and remained low in the treatment group, resulting in an effacement of group differences that were present pre-COVID-19. These outcomes did not result from changes in provider- or disease-dependent factors; pulmonary artery pressure decreased despite fewer medication changes, suggesting that patient-dependent factors played an important role in these outcomes. Clinical Trials.gov: NCT03387813.
引用
- Zile, Desai, Costanzo, et al. The GUIDE-HF trial of pulmonary artery pressure monitoring in heart failure: impact of the COVID-19 pandemic. Eur Heart J. 2022. PMID: 35266003. doi:10.1093/eurheartj/ehac114
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。